Trial report in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01206062 (Systolic Blood Pressure Intervention Trial), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2010 to 2019Enrolled9,361ConditionsHypertensionArmsIntensive control of SBP, Standard control of SBP
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Chenyu FanDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0000-0001-7878-2629
Xuan WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.W., Y.P., Z.L., Y.W.).ORCID 0000-0001-5929-6916
Liyuan TaoResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China (L.T.).ORCID 0000-0003-3497-1326
Yundan LiaoPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China (Y.L., W.Y.).ORCID 0000-0002-0969-6927
Ling JinDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0000-0002-0687-9234
Quanyou ShiDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0009-0004-2844-863X
Hu WangDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0009-0009-6913-9514
Yidan ShiDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).
Tianqi ChangDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0000-0002-6490-6421
Yuzhou XueDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0009-0005-4212-7717
Jiaxing WangDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0000-0001-7735-0955
Weihua YuePeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China (Y.L., W.Y.).ORCID 0000-0002-1201-8465
Yuesong PanDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.W., Y.P., Z.L., Y.W.).ORCID 0000-0003-3082-6789
Zixiao LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.W., Y.P., Z.L., Y.W.).ORCID 0000-0002-4713-5418
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.W., Y.P., Z.L., Y.W.).ORCID 0000-0002-9976-2341
Ming XuDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China (C.F., L.J., Q.S., H.W., Y.S., T.C., Y.X., J.W., M.X.).ORCID 0000-0003-1680-3628
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundThe influence of IR (insulin resistance) on the response of patients with hypertension to intensive systolic blood pressure treatment in terms of cognitive performance remains unclear, as does which circulating metabolites mediate this process.
methodsThis study comprised a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial). The SPRINT study enrolled 9361 participants aged ≥50 years with hypertension, of whom 7427 were analyzed. SPRINT participants were assigned to either intensive (<120 mm Hg) or standard systolic blood pressure treatment (<140 mm Hg). The primary cognitive outcome was probable dementia. Cox proportional hazards models, restricted cubic splines, and linear mixed models assessed the influence of systolic blood pressure control on cognitive functions and white matter hyperintensities across different triglyceride-glucose (TyG) levels. Mendelian randomization was used to estimate the mediation effect of circulating metabolites on the relationship between IR and cognitive outcomes.
resultsAmong participants with elevated IR (TyG >9.07), intensive treatment was associated with a reduced risk of probable dementia and a slower progression of white matter hyperintensities. Our mediation analysis identified a potential pathway linking the TyG index to dementia via plasma glycosyl ceramide levels, accounting for ≈10.8% of the total effect.
conclusionsIn patients with hypertension with TyG >9.07, lowering blood pressure to <120 mm Hg reduced dementia incidence more than standard control, hinting TyG modifies treatment effects, possibly via glycosyl ceramide. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Insulin Resistance and Blood Pressure Control on Cognitive Outcomes. · full record | Socratic